View More Recent Stories
-
Mirum Pharmaceuticals (MIRM) PT Raised to $76 at Citizens JMP
-
Mirum Pharamceuticals (MIRM) PT Raised to $76 at Evercore ISI
-
Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 1c ; Offers Guidance
-
Mirum Pharmaceuticals' (MIRM) LIVMARLI in tablet form receives FDA approval
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Mirum (MIRM) partner Takeda receives LIVMARLI approval in Japan
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Mirum Pharamceuticals (MIRM) PT Raised to $72 at H.C. Wainwright
-
Mirum Pharmaceuticals, Inc. (MIRM) Misses Q4 EPS by 155c
-
Mirum Pharmaceuticals' (MIRM) CTEXLI Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis
-
Citizens JMP Reiterates Market Outperform Rating on Mirum Pharamceuticals (MIRM)
-
FDA approves Mirum Pharmaceuticals' (MIRM) genetic disorder drug
-
Mirum Pharmaceuticals (MIRM) Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
-
H.C. Wainwright Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharamceuticals (MIRM) PT Raised to $70 at Stifel
-
Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 15c ; Offers Guidance
-
H.C. Wainwright Reiterates Buy Rating on Mirum Pharamceuticals (MIRM), 'affirm MIRM shares as one of our 2024 Top Picks'
-
Mirum Pharmaceuticals (MIRM) Announces Volixibat Granted FDA Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
-
Mirum Pharamceuticals (MIRM) PT Raised to $44 at Baird
-
Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 5c ; Offers Guidance
-
Mirum Pharmaceuticals, Inc. (MIRM) August 40 and 45 calls active as share price up 6.5%
-
Mirum Pharmaceuticals (MIRM) said approached by Sobi about a takeover - source
-
Mirum Pharmaceuticals' (MIRM) LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
-
Mirum Pharamceuticals (MIRM) PT Raised to $69 at JMP Securities
-
Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
H.C. Wainwright Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharamceuticals (MIRM) PT Raised to $66 at H.C. Wainwright
-
Mirum Pharamceuticals (MIRM) PT Raised to $62 at Evercore ISI
-
Mirum Pharamceuticals (MIRM) PT Raised to $64 at Citi
-
Mirum Pharamceuticals (MIRM) PT Raised to $57 at Morgan Stanley
-
Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird
-
Citi Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
-
Mirum Pharmaceuticals' (MIRM) Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

